Celularity Research Development vs Cost Of Revenue Analysis

CELUW Stock

USD 0.02 0.0004 1.79%

Celularity financial indicator trend analysis is way more than just evaluating Celularity prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Celularity is a good investment. Please check the relationship between Celularity Research Development and its Cost Of Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celularity. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Celularity Stock please use our How to Invest in Celularity guide.

Research Development vs Cost Of Revenue

Research Development vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Celularity Research Development account and Cost Of Revenue. At this time, the significance of the direction appears to have weak relationship.

The correlation between Celularity's Research Development and Cost Of Revenue is 0.33. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of Celularity, assuming nothing else is changed. The correlation between historical values of Celularity's Research Development and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Celularity are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Research Development i.e., Celularity's Research Development and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

0.33

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Research Development

Cost Of Revenue

Cost of Revenue is found on Celularity income statement and represents the costs associated with goods and services Celularity provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from Celularity's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Celularity current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celularity. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Celularity Stock please use our How to Invest in Celularity guide.Tax Provision is likely to climb to about 10.5 K in 2024, whereas Selling General Administrative is likely to drop slightly above 48.1 M in 2024.

	2021	2023	2024 (projected)
Interest Expense	3.2M	3.0M	2.5M
Depreciation And Amortization	51.1M	10.8M	20.6M

Interest Expense Depreciation And Amortization

Celularity fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Net Tangible Assets	Property Plant And Equipment Net	Warrants	Accounts Payable	Net Receivables	Good Will	Common Stock Total Equity	Retained Earnings Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse
Total Assets		0.61	0.82	0.54	-0.08	0.22	-0.68	0.8	1.0	-0.18	0.8	0.56	0.74	0.83	0.27	-0.7	0.81	-0.7	0.41	0.56	-0.09	0.73	-0.81	0.52	0.67	0.79
Short Long Term Debt Total	0.61		0.46	0.97	0.16	0.77	-0.92	0.23	0.61	0.03	0.54	0.94	0.32	0.6	0.07	-0.91	0.8	-0.91	0.8	0.91	-0.8	0.9	-0.85	0.92	0.18	0.81
Other Current Liab	0.82	0.46		0.52	-0.41	0.01	-0.66	0.87	0.78	0.35	0.83	0.39	0.84	0.9	-0.28	-0.68	0.82	-0.68	0.31	0.55	0.01	0.71	-0.82	0.52	0.79	0.8
Total Current Liabilities	0.54	0.97	0.52		0.07	0.72	-0.95	0.24	0.52	0.26	0.55	0.93	0.32	0.62	-0.17	-0.94	0.82	-0.94	0.81	0.94	-0.8	0.93	-0.87	0.95	0.19	0.84
Total Stockholder Equity	-0.08	0.16	-0.41	0.07		0.64	0.08	-0.59	-0.02	-0.41	-0.54	0.36	-0.73	-0.53	0.42	0.13	-0.19	0.13	0.07	-0.11	-0.08	-0.14	0.18	0.02	-0.78	-0.17
Net Debt	0.22	0.77	0.01	0.72	0.64		-0.5	-0.35	0.25	-0.2	-0.09	0.76	-0.28	0.02	0.25	-0.48	0.32	-0.47	0.48	0.56	-0.63	0.45	-0.38	0.68	-0.4	0.35
Retained Earnings	-0.68	-0.92	-0.66	-0.95	0.08	-0.5		-0.5	-0.66	-0.29	-0.76	-0.9	-0.52	-0.78	0.19	1.0	-0.93	1.0	-0.87	-0.94	0.72	-1.0	0.97	-0.9	-0.4	-0.94
Cash	0.8	0.23	0.87	0.24	-0.59	-0.35	-0.5		0.76	0.17	0.91	0.16	0.94	0.89	-0.1	-0.53	0.7	-0.53	0.23	0.36	0.14	0.56	-0.67	0.24	0.94	0.66
Non Current Assets Total	1.0	0.61	0.78	0.52	-0.02	0.25	-0.66	0.76		-0.23	0.76	0.56	0.7	0.79	0.32	-0.67	0.78	-0.67	0.4	0.54	-0.07	0.7	-0.78	0.5	0.63	0.77
Non Currrent Assets Other	-0.18	0.03	0.35	0.26	-0.41	-0.2	-0.29	0.17	-0.23		0.23	0.1	0.15	0.24	-0.99	-0.29	0.28	-0.29	0.24	0.26	-0.17	0.29	-0.29	0.24	0.15	0.28
Cash And Short Term Investments	0.8	0.54	0.83	0.55	-0.54	-0.09	-0.76	0.91	0.76	0.23		0.46	0.92	0.97	-0.15	-0.79	0.88	-0.79	0.52	0.64	-0.28	0.81	-0.86	0.51	0.87	0.82
Other Stockholder Equity	0.56	0.94	0.39	0.93	0.36	0.76	-0.9	0.16	0.56	0.1	0.46		0.14	0.48	0.0	-0.87	0.77	-0.87	0.84	0.83	-0.76	0.86	-0.81	0.85	0.0	0.77
Total Liab	0.74	0.32	0.84	0.32	-0.73	-0.28	-0.52	0.94	0.7	0.15	0.92	0.14		0.93	-0.09	-0.57	0.69	-0.57	0.24	0.46	-0.01	0.59	-0.68	0.34	0.99	0.66
Total Current Assets	0.83	0.6	0.9	0.62	-0.53	0.02	-0.78	0.89	0.79	0.24	0.97	0.48	0.93		-0.15	-0.81	0.9	-0.81	0.47	0.68	-0.26	0.84	-0.89	0.59	0.87	0.85
Common Stock	0.27	0.07	-0.28	-0.17	0.42	0.25	0.19	-0.1	0.32	-0.99	-0.15	0.0	-0.09	-0.15		0.19	-0.18	0.19	-0.15	-0.17	0.11	-0.19	0.19	-0.16	-0.1	-0.18
Net Tangible Assets	-0.7	-0.91	-0.68	-0.94	0.13	-0.48	1.0	-0.53	-0.67	-0.29	-0.79	-0.87	-0.57	-0.81	0.19		-0.93	1.0	-0.85	-0.95	0.71	-1.0	0.97	-0.9	-0.45	-0.95
Property Plant And Equipment Net	0.81	0.8	0.82	0.82	-0.19	0.32	-0.93	0.7	0.78	0.28	0.88	0.77	0.69	0.9	-0.18	-0.93		-0.93	0.64	0.77	-0.47	0.95	-0.97	0.72	0.59	0.89
Warrants	-0.7	-0.91	-0.68	-0.94	0.13	-0.47	1.0	-0.53	-0.67	-0.29	-0.79	-0.87	-0.57	-0.81	0.19	1.0	-0.93		-0.85	-0.95	0.7	-1.0	0.98	-0.9	-0.45	-0.95
Accounts Payable	0.41	0.8	0.31	0.81	0.07	0.48	-0.87	0.23	0.4	0.24	0.52	0.84	0.24	0.47	-0.15	-0.85	0.64	-0.85		0.89	-0.81	0.82	-0.76	0.85	0.12	0.81
Net Receivables	0.56	0.91	0.55	0.94	-0.11	0.56	-0.94	0.36	0.54	0.26	0.64	0.83	0.46	0.68	-0.17	-0.95	0.77	-0.95	0.89		-0.78	0.92	-0.88	0.98	0.34	0.91
Good Will	-0.09	-0.8	0.01	-0.8	-0.08	-0.63	0.72	0.14	-0.07	-0.17	-0.28	-0.76	-0.01	-0.26	0.11	0.71	-0.47	0.7	-0.81	-0.78		-0.67	0.53	-0.76	0.11	-0.5
Common Stock Total Equity	0.73	0.9	0.71	0.93	-0.14	0.45	-1.0	0.56	0.7	0.29	0.81	0.86	0.59	0.84	-0.19	-1.0	0.95	-1.0	0.82	0.92	-0.67		-0.98	0.87	0.48	0.95
Retained Earnings Total Equity	-0.81	-0.85	-0.82	-0.87	0.18	-0.38	0.97	-0.67	-0.78	-0.29	-0.86	-0.81	-0.68	-0.89	0.19	0.97	-0.97	0.98	-0.76	-0.88	0.53	-0.98		-0.84	-0.57	-0.97
Common Stock Shares Outstanding	0.52	0.92	0.52	0.95	0.02	0.68	-0.9	0.24	0.5	0.24	0.51	0.85	0.34	0.59	-0.16	-0.9	0.72	-0.9	0.85	0.98	-0.76	0.87	-0.84		0.21	0.87
Non Current Liabilities Total	0.67	0.18	0.79	0.19	-0.78	-0.4	-0.4	0.94	0.63	0.15	0.87	0.0	0.99	0.87	-0.1	-0.45	0.59	-0.45	0.12	0.34	0.11	0.48	-0.57	0.21		0.56
Capital Surpluse	0.79	0.81	0.8	0.84	-0.17	0.35	-0.94	0.66	0.77	0.28	0.82	0.77	0.66	0.85	-0.18	-0.95	0.89	-0.95	0.81	0.91	-0.5	0.95	-0.97	0.87	0.56

Click cells to compare fundamentals

Celularity Account Relationship Matchups

Celularity fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	291.6M	431.0M	414.1M	401.1M	143.9M	136.7M
Short Long Term Debt Total	28.1M	30.6M	31.1M	65.6M	75.4M	79.2M
Other Current Liab	(3.5M)	18.3M	11.7M	16.4M	2.4M	2.3M
Total Current Liabilities	229.1K	26.7M	26.2M	62.1M	67.3M	70.7M
Total Stockholder Equity	263.4M	(531.4M)	99.4M	198.9M	41.0M	43.0M
Net Debt	27.1M	(23.7M)	(6.1M)	51.6M	39.0M	41.0M
Retained Earnings	3.9M	(563.6M)	(663.7M)	(645.5M)	(841.8M)	(799.7M)
Cash	917.0K	54.3M	37.2M	14.0M	227K	215.7K
Non Current Assets Total	290.6M	358.8M	376.9M	367.6M	124.1M	117.9M
Non Currrent Assets Other	(464.9M)	20.1M	39.8M	23.3M	26.9M	28.3M
Cash And Short Term Investments	917.0K	54.3M	37.2M	14.0M	16.1M	23.4M
Liabilities And Stockholders Equity	291.6M	431.0M	414.1M	401.1M	461.2M	338.4M
Other Stockholder Equity	259.5M	32.2M	763.1M	844.4M	971.0M	1.0B
Total Liab	28.2M	962.4M	314.7M	202.2M	102.9M	97.8M
Total Current Assets	1.0M	72.2M	37.2M	33.5M	19.8M	30.0M
Common Stock	258.4M	1K	12K	15K	13.5K	12.8K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Celularity Stock Analysis

When running Celularity's price analysis, check to measure Celularity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celularity is operating at the current time. Most of Celularity's value examination focuses on studying past and present price action to predict the probability of Celularity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celularity's price. Additionally, you may evaluate how the addition of Celularity to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Celularity Research Development vs Cost Of Revenue Analysis

Research Development vs Cost Of Revenue

Research Development vs Cost Of Revenue Correlation Analysis

Correlation Coefficient

Research Development

Cost Of Revenue

Celularity fundamental ratios Correlations

Celularity Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Celularity fundamental ratios Accounts

Also Currently Popular

Additional Tools for Celularity Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Retained Earnings
Warrants	+ 1.0	Retained Earnings
Warrants	+ 1.0	Net Tangible Assets
Non Current Liabilities Total	+ 0.99	Total Liab
Retained Earnings Total Equity	+ 0.98	Warrants

Common Stock Total Equity	- 1.0	Warrants
Common Stock Total Equity	- 1.0	Net Tangible Assets
Common Stock Total Equity	- 1.0	Retained Earnings
Common Stock	- 0.99	Non Currrent Assets Other
Retained Earnings Total Equity	- 0.98	Common Stock Total Equity
Capital Surpluse	- 0.97	Retained Earnings Total Equity